Table.2.
Crude and adjusted associations between different variables and clinical failure at day 7 and at end of treatment in overall and propensity-matched cohorts
| Overall cohort | Propensity-matched cohorts | ||||
|---|---|---|---|---|---|
| Crude OR (95% CI) | aOR (95% CI) | p value | aOR (95% CI) | p value | |
| Day 7 | |||||
| Age (years), m (IQR) | 1.01 (1–1.09) | 1.05 (1.01–1.1) | 0.041 | 1.01 (0.96–1.06) | 0.725 |
| Charlson comorbidity index, m (IQR) | 1.06 (0.89–1.25) | 1.09 (0.9–1.32) | 0.356 | 1.05 (0.81–1.35) | 0.717 |
| SOFA score, m (IQR) | 1.12 (0.9–1.38) | 1.01 (0.82–1.31) | 0.770 | 1.13 (0.82–1.55) | 0.460 |
| Amikacin or CMS treatment | 0.38 (0.15–0.95) | 0.5 (0.17–1.44) | 0.198 | 0.53 (0.18–1.58) | 0.251 |
| Propensity score | 0.16 (0.03–0.86) | 0.34 (0.04–2.74) | 0.311 | ||
| End of treatment | |||||
| Age (years), m (IQR) | 1.03 (0.98–1.08) | 1.05 (0.99–1.11) | 0.101 | 1.04 (0.97–1.19) | 0.301 |
| Charlson comorbidity index, m (IQR) | 1.18 (0.98–1.43) | 1.24 (1.01–1.53) | 0.047 | 1.39 (0.97–1.97) | 0.071 |
| SOFA score, m (IQR) | 1.05 (0.82–1.34) | 1 (0.76–1.31) | 0.980 | 0.88 (0.57–1.36) | 0.552 |
| Amikacin or CMS treatment | 1.13 (0.42–3.01) | 1.58 (0.47–5.32) | 0.462 | 1.29 (0.34–4.83) | 0.707 |
| Propensity score | 0.48 (0.07–3.2) | 0.35 (0.31–4) | 0.401 | ||
SOFA Sequential Organ Failure Assessment, ICU intensive care unit, CMS colistimethate sodium, m median, IQR interquartile range, OR odds ratio, aOR adjusted odds ratio, CI confidence interval